Integrating Phenotypic and Genotypic Resistance Data

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-27

Quick Answer

• Combine phenotypic minimum inhibitory concentration (MIC) results with whole-genome sequencing (WGS) resistance gene predictions using a harmonized data structure that maps both data types to the same antimicrobial agent identifiers.
• Calculate concordance metrics such as categorical agreement and essential agreement to quantify how often genotypic predictions match phenotypic susceptibility categories, then investigate every discordant case individually.
• Discordance does not automatically indicate an error, because gene presence does not always produce resistance and resistance can arise through mutations or efflux mechanisms that gene detection alone may miss.

At a Glance

The Problem of Two Different Resistance Languages

Clinical microbiology laboratories and research groups increasingly generate both phenotypic antimicrobial susceptibility testing (AST) results and whole-genome sequencing data for the same bacterial isolates. Phenotypic AST measures the observable response of a bacterial isolate to an antimicrobial agent under standardized conditions, typically expressed as a minimum inhibitory concentration (MIC) or a categorical interpretation such as susceptible, intermediate, or resistant. Genotypic analysis searches the bacterial genome for known resistance determinants, including acquired resistance genes and chromosomal point mutations that confer resistance. Each approach provides a distinct view of antimicrobial resistance, and neither alone fully explains the resistance profile of an isolate.

The challenge for a bioinformatician or clinical microbiologist is practical. You may have a spreadsheet of MIC values from an automated susceptibility testing instrument and a separate directory of assembled genomes with resistance gene annotations from a bioinformatics pipeline. To make a confident assessment of an isolate, you need to combine these data types in a way that reveals concordance and highlights discrepancies. A reproducible pipeline for merging these data types must address data harmonization, concordance metrics, and visualization of discordant cases. This article provides a practical approach to that integration problem.

The global context for this work is the growing burden of antimicrobial resistance. The World Health Organization describes antimicrobial resistance as a process in which bacteria change over time and no longer respond to medicines, making infections harder to treat and increasing the risk of disease spread, severe illness, and death. Surveillance of resistance at both the phenotypic and genomic level is a core component of the global response. The WHO emphasizes that antimicrobial resistance is driven by misuse and overuse of antimicrobials in human health, animal health, and food production, and that surveillance data are needed to guide stewardship decisions. Your integrated analysis contributes directly to this surveillance effort.

Core Principles of Phenotypic and Genotypic Resistance Data

Phenotypic Antimicrobial Susceptibility Testing

Phenotypic AST is the traditional reference approach for determining whether a bacterial isolate is susceptible or resistant to an antimicrobial agent. The Clinical and Laboratory Standards Institute (CLSI) publishes standards and guidelines for antimicrobial susceptibility testing that are used widely in clinical laboratories. These standards define the methods for performing tests, the conditions for incubation, the quality control organisms that must be used, and the interpretive criteria that translate a measured MIC or zone diameter into a categorical result. The CLSI standards are updated regularly, and laboratories must use the current edition to ensure that their results are comparable across time and across laboratories.

The most common methods are broth microdilution, which produces a numeric MIC value, and disk diffusion, which produces a zone diameter measurement. Both methods require a pure culture of the organism, standardized inoculum preparation, and controlled incubation conditions. The results are interpreted using breakpoints that define the concentration at which an isolate is considered susceptible or resistant. These breakpoints are established based on pharmacokinetic and pharmacodynamic data, clinical outcome data, and the distribution of MICs among wild-type populations.

Phenotypic testing has a critical limitation that matters for integration with genomic data. The result is a measurement of the interaction between the bacterium and the drug under specific laboratory conditions. It does not tell you why the bacterium is resistant. A resistant result could be due to an acquired resistance gene, a chromosomal mutation, a change in membrane permeability, an efflux pump, or a combination of mechanisms. Phenotypic testing also requires a viable culture, which means it cannot be performed on samples that are no longer viable or on metagenomic data.

Genotypic Resistance Prediction from Whole-Genome Sequencing

Whole-genome sequencing provides a different type of information. The sequence of the bacterial genome contains the genetic blueprint for all potential resistance mechanisms. Bioinformatics pipelines typically assemble the sequencing reads into contigs, then compare the assembled genome against curated databases of known resistance genes and point mutations. The output is a list of predicted resistance determinants, often with a percentage identity and coverage value that indicates how closely the detected sequence matches the database entry.

Genotypic prediction has several advantages. It can be performed on DNA extracted from a culture or directly from a clinical sample, it does not require a viable organism, and it can detect resistance genes that are present but not expressed under the tested conditions. It also provides information about the genetic context of the resistance, such as whether a gene is located on a plasmid or in the chromosome, which is useful for understanding the potential for horizontal gene transfer.

The limitation of genotypic prediction is that it is a prediction. The presence of a resistance gene does not guarantee that the gene is expressed at a level sufficient to confer resistance. A gene may be truncated, disrupted by an insertion sequence, or regulated in a way that prevents expression. Conversely, resistance can arise through mutations in genes that are not in the resistance database, or through mechanisms such as efflux pumps that are encoded by genes present in all members of a species but overexpressed in resistant strains. These mechanisms are difficult to predict from a static genome sequence alone.

Why Concordance Is Not Automatic

The two data types measure different biological phenomena. Phenotypic testing measures the outcome of all resistance mechanisms acting together in a living cell. Genotypic prediction measures the presence of genetic determinants that are known to be associated with resistance. The relationship between the two is probabilistic, not deterministic. A gene that is known to confer resistance to a specific drug will usually produce a resistant phenotype, but there are exceptions. Conversely, a resistant phenotype can occur in the absence of any known resistance gene.

This is why a simple comparison of the two data types is not sufficient. You need a systematic approach that quantifies the level of agreement, identifies the specific cases where the two data types disagree, and provides a framework for interpreting those disagreements. The remainder of this article describes a reproducible pipeline for achieving this integration.

Building a Reproducible Pipeline for Data Integration

Step 1: Define the Scope and Organism Set

The first decision is to define the scope of the analysis. You need to specify the bacterial species or genus that you are analyzing, the set of antimicrobial agents that you will compare, and the source of the isolates. The choice of species matters because the resistance gene databases and the interpretation of point mutations are species-specific. A gene that confers resistance in one species may not have the same effect in another species.

The choice of antimicrobial agents matters because the concordance between phenotypic and genotypic data varies by drug. For some drugs, the genetic basis of resistance is well understood and the concordance is high. For other drugs, the mechanisms are more complex and the concordance is lower. The analysis should focus on the drugs that are most relevant to the clinical or research question.

The source of the data matters for the interpretation. Clinical isolates from a hospital have a different resistance profile than environmental isolates or food isolates. The analysis should be designed to answer a specific question, such as whether a new genotypic prediction tool is accurate for a specific species, or whether a specific resistance gene is reliably associated with a resistant phenotype in a collection of isolates.

Step 2: Harmonize the Data

The most common source of errors in an integrated analysis is inconsistent data formatting. The phenotypic data and the genomic data are likely to come from different sources, and the antimicrobial names, the isolate identifiers, and the result formats are likely to be different. The first step is to create a single data table that contains one row per isolate per antimicrobial agent.

The isolate identifier is the primary key that links the two data types. The identifier must be consistent between the phenotypic data and the genomic data. If the identifiers are not identical, you must create a mapping table that links the two identifiers. This is a common source of error, and it is worth spending time to verify that the mapping is correct.

The antimicrobial agent names must also be harmonized. The phenotypic data may use a drug name such as "ciprofloxacin," while the genomic data may use a gene name such as "gyrA" or a mutation such as "S83L." The comparison must be made at the level of the antimicrobial agent, not the gene. You need a mapping table that links each gene or mutation to the antimicrobial agent that it affects. This mapping is not always one to one. A single gene can confer resistance to multiple drugs, and a single drug can be affected by multiple genes.

The result formats must also be harmonized. The phenotypic data may be a numeric MIC value, a categorical result, or a zone diameter. The genotypic data may be a list of genes with a binary presence or absence, or a list of mutations with a predicted effect. The analysis requires a common format. The most useful format is a binary classification for each isolate and each drug, where the isolate is classified as resistant or not resistant based on the phenotypic data, and as having a resistance determinant or not having a resistance determinant based on the genomic data.

Step 3: Define the Concordance Metrics

The concordance between the phenotypic and genotypic data is typically measured using a set of standard metrics. The most important metric is the categorical agreement, which is the percentage of isolates for which the genotypic prediction matches the phenotypic result. This is calculated as the number of isolates with a resistant phenotype and a resistance determinant, plus the number of isolates with a susceptible phenotype and no resistance determinant, divided by the total number of isolates.

The sensitivity of the genotypic prediction is the percentage of phenotypically resistant isolates that have a resistance determinant. This is calculated as the number of isolates with a resistant phenotype and a resistance determinant divided by the total number of phenotypically resistant isolates. The specificity is the percentage of phenotypically susceptible isolates that have no resistance determinant. The positive predictive value is the percentage of isolates with a resistance determinant that are phenotypically resistant, and the negative predictive value is the percentage of isolates without a resistance determinant that are phenotypically susceptible.

These metrics are useful for quantifying the overall performance of the genotypic prediction, but they do not identify the specific cases that need investigation. The analysis should also produce a list of discordant cases, which are the isolates where the two data types disagree. These are the cases that require manual review.

Step 4: Visualize the Discordant Cases

The visualization of discordant cases is an essential part of the analysis. A simple table of discordant isolates is useful, but a visual representation can help identify patterns. A scatter plot of the MIC values for each isolate, colored by the presence or absence of a resistance determinant, can show whether the discordant cases are clustered at the breakpoint or spread across the range of MIC values. A heatmap of the resistance determinants and the phenotypic results can show whether the discordance is associated with a specific gene or a specific drug.

The visualization should be designed to answer the question of why the discordance occurs. The most common pattern is that the discordant isolates have a MIC value that is close to the breakpoint. In this case, the discordance may be due to the inherent variability of the phenotypic test or to the fact that the breakpoint is a threshold that does not perfectly separate the resistant and susceptible populations. Another common pattern is that the discordant isolates have a resistance determinant that is not expressed, or a resistance mechanism that is not captured by the gene prediction.

A Practical Workflow for the Analysis

The following workflow is a practical approach to integrating phenotypic and genotypic data. The workflow is designed to be reproducible and to produce a clear record of the analysis.

Step 1: Prepare the Phenotypic Data

The phenotypic data should be exported from the laboratory information system or the AST instrument in a tabular format. The table should contain at least the isolate identifier, the antimicrobial agent name, and the MIC value or categorical result. The data should be checked for missing values, duplicate entries, and inconsistent drug names. The drug names should be standardized to a single naming convention, such as the CLSI standard abbreviations.

Step 2: Prepare the Genotypic Data

The genotypic data should be exported from the bioinformatics pipeline in a tabular format. The table should contain at least the isolate identifier, the resistance gene name or mutation, and a confidence score or percentage identity. The data should be checked for missing values and for genes that are not relevant to the antimicrobial agents in the analysis. The gene names should be mapped to the antimicrobial agents that they affect.

Step 3: Merge the Data

The two tables should be merged on the isolate identifier and the antimicrobial agent. The merged table should have one row per isolate per drug, with columns for the phenotypic result and the genotypic prediction. The genotypic prediction should be a binary variable that indicates whether a resistance determinant is present for that drug. The merge should be checked for missing rows, which may indicate that an isolate is missing from one of the data sources.

Step 4: Calculate the Concordance Metrics

The concordance metrics should be calculated using a script or a statistical software package. The metrics should include the categorical agreement, sensitivity, specificity, positive predictive value, and negative predictive value. The metrics should be calculated for each drug separately and for the overall dataset. The metrics should be reported with the number of isolates in each category.

Step 5: Identify and Review the Discordant Cases

The discordant cases should be identified as the isolates where the phenotypic result and the genotypic prediction disagree. Each discordant case should be reviewed individually. The review should consider the MIC value, the specific resistance determinant, the quality of the genome assembly, and the possibility of a technical error. The review should be documented in a table that records the reason for the discordance and the final interpretation.

Step 6: Visualize the Results

The results should be visualized using a scatter plot of the MIC values, a heatmap of the resistance determinants, and a summary table of the concordance metrics. The visualization should be designed to communicate the overall concordance and the specific discordant cases. The visualization should be included in the final report.

flowchart TD
    A[Phenotypic AST data] --> C[Data harmonization]
    B[WGS resistance gene predictions] --> C
    C --> D[Merged isolate drug table]
    D --> E[Concordance metrics]
    D --> F[Discordant case list]
    E --> G[Summary report]
    F --> H[Manual review of discordant cases]
    H --> G

Records and Measurements for the Analysis

The Minimum Data Set

The minimum data set for a concordance analysis is a table with one row per isolate per drug. The table must contain the isolate identifier, the drug name, the phenotypic result, and the genotypic prediction. The phenotypic result should be recorded as a categorical result, such as susceptible or resistant, and the MIC value should be recorded when available. The genotypic prediction should be recorded as a binary variable that indicates whether a resistance determinant is present.

The Quality Control Data

The quality of the analysis depends on the quality of the input data. The phenotypic data should be generated using a standardized method, such as the methods described in the CLSI standards. The quality control organisms should be tested in parallel with the clinical isolates to ensure that the test is performing correctly. The genotypic data should be generated from a high-quality genome assembly, and the resistance gene prediction should be performed using a validated database and a validated pipeline.

The American Type Culture Collection (ATCC) provides authenticated biological materials, including quality control strains for antimicrobial susceptibility testing. The use of authenticated reference strains is important for ensuring that the phenotypic data are reliable and that the genotypic data can be compared across laboratories. The ATCC collection is a source of well-characterized strains that can be used as positive and negative controls for the analysis.

The Records That Should Be Kept

The analysis should be documented in a way that is reproducible. The raw data files, the scripts used for the analysis, and the version numbers of the software and databases should be recorded. The records should include the date of the analysis, the version of the resistance gene database, and the version of the AST method. The records should be kept in a version-controlled repository to ensure that the analysis can be repeated or updated.

Common Failure Patterns and How to Address Them

Failure Pattern 1: The Isolate Identifier Does Not Match

The most common failure is that the isolate identifier in the phenotypic data does not match the isolate identifier in the genomic data. This can occur when the identifiers are formatted differently, such as one using a leading zero and the other not, or when the identifiers have been truncated or modified during the data transfer. The solution is to create a mapping table that links the two identifiers, and to verify the mapping by checking a sample of the isolates.

Failure Pattern 2: The Drug Name Is Not Standardized

The drug names in the phenotypic data may not match the drug names in the genomic data. The phenotypic data may use a brand name or a common abbreviation, while the genomic data may use a different abbreviation or a database name. The solution is to create a mapping table that links the drug names, and to use a single standardized naming convention throughout the analysis.

Failure Pattern 3: The Genotypic Prediction Is Not Specific to the Drug

The genotypic prediction may be a gene that confers resistance to a class of drugs, but the phenotypic data may be for a specific drug within that class. For example, a gene that confers resistance to all beta-lactams may be present, but the phenotypic data may be for a specific beta-lactam such as ceftriaxone. The solution is to map the gene to the specific drug, and to be aware that the gene may not confer resistance to all drugs in the class.

Failure Pattern 4: The Discordant Cases Are Not Reviewed

The most common failure is to calculate the concordance metrics and stop, without reviewing the discordant cases. The discordant cases are the most informative part of the analysis, because they reveal the limitations of the genotypic prediction and the phenotypic test. The solution is to review each discordant case individually and to document the reason for the discordance.

Failure Pattern 5: The Analysis Is Not Reproducible

The analysis may be performed manually, with the data manipulated in a spreadsheet and the metrics calculated by hand. This is not reproducible, and it is prone to errors. The solution is to use a script or a script that can be run again with the same input data and produce the same output.

The Role of Reference Materials and Quality Control

Authenticated Biological Materials

The use of authenticated biological materials is a critical component of the analysis. The American Type Culture Collection (ATCC) provides authenticated strains that are used for quality control in microbiology. These strains are characterized for their phenotypic and genotypic properties, and they are used to validate the performance of the AST method and the genotypic prediction pipeline. The use of authenticated strains ensures that the results are comparable across laboratories and across time.

The ATCC strains are also used for the validation of the resistance gene databases. The databases are built from the sequences of known resistance genes, and the validation of the databases requires strains with known resistance properties. The use of authenticated strains with known resistance genes is essential for the validation of the genotypic prediction.

The CLSI Standards for AST

The CLSI standards for antimicrobial susceptibility testing are the reference for the phenotypic data. The standards describe the methods for the testing, the quality control requirements, and the interpretive criteria. The standards are updated periodically, and the laboratory must use the current edition. The CLSI standards are not freely available, and the breakpoints are not reproduced in this article. The laboratory should obtain the current edition of the CLSI standards and follow the methods described in the standards.

The FDA Bacteriological Analytical Manual

The FDA Bacteriological Analytical Manual (BAM) provides official methods for the detection and identification of foodborne bacteria. The BAM methods are used in food safety laboratories, and they include methods for the isolation and identification of bacteria from food samples. The BAM is a source of methods for the phenotypic characterization of foodborne bacteria, and it is a reference for the quality of the analytical methods.

The Interpretation of Discordant Cases

The Discordant Case Where the Genotype Is Resistant and the Phenotype Is Susceptible

This is the case where a resistance determinant is present in the genome, but the isolate is phenotypically susceptible. The possible explanations are that the gene is not expressed, that the gene is not functional, or that the gene is present but the phenotype is not resistant because the gene is not the dominant mechanism. The review should include an examination of the gene sequence to determine whether the gene is intact or disrupted, and an examination of the MIC value to determine whether the isolate is close to the breakpoint.

The Discordant Case Where the Genotype Is Susceptible and the Phenotype Is Resistant

This is the case where the isolate is phenotypically resistant, but no resistance determinant is detected in the genome. The possible explanations are that the resistance is due to a mechanism that is not in the database, such as an efflux pump or a mutation in a gene that is not annotated, or that the resistance is due to a gene that is present but not detected by the pipeline. The review should include an examination of the MIC value and a search for other resistance mechanisms.

The Discordant Case Where the MIC Is Close to the Breakpoint

The discordance may be due to the inherent variability of the phenotypic test. The MIC value is a measurement that has a certain amount of variability, and the breakpoint is a threshold that is used to classify the isolate. An isolate with a MIC value that is close to the breakpoint may be classified as resistant in one test and susceptible in another test. The review should consider the MIC value and the reproducibility of the test.

The Role of the Analysis in the Laboratory

The Use of the Analysis for Clinical Decisions

The integrated analysis is used to support clinical decisions about the treatment of infections. The phenotypic AST is the reference for the clinical decision, and the genotypic prediction is used to provide additional information about the resistance mechanisms. The genotypic data can be used to identify the resistance mechanism, which can be useful for the selection of the treatment. The genotypic data can also be used to detect resistance that is not detected by the phenotypic test, such as resistance that is inducible or resistance that is not expressed under the test conditions.

The Use of the Analysis for Surveillance

The integrated analysis is used for the surveillance of antimicrobial resistance. The surveillance data are used to track the spread of resistance genes and to identify the emergence of new resistance mechanisms. The World Health Organization describes the surveillance of antimicrobial resistance as a core component of the global response to the problem. The surveillance data are used to inform the stewardship of antimicrobial use and to guide the development of new drugs.

The Use of the Analysis for Research

The integrated analysis is used for research on the mechanisms of resistance. The comparison of the phenotypic and genotypic data can reveal the cases where the gene prediction is not accurate, and these cases are the subject of further research. The research can lead to the identification of new resistance mechanisms and the improvement of the gene prediction databases.

The Limitations of the Integrated Analysis

The Limitations of the Phenotypic Data

The phenotypic data are limited by the conditions of the test. The MIC value is a measure of the growth of the bacterium under a specific set of conditions, and the conditions may not reflect the conditions in the patient. The phenotypic test is also limited by the breakpoints, which are established for the clinical context and may not be appropriate for the research context.

The Limitations of the Genotypic Data

The genotypic data are limited by the content of the database. The database contains the sequences of the known resistance genes, and the prediction is limited to the genes that are in the database. The database is not complete, and the prediction may miss the resistance genes that are not in the database. The genotypic data are also limited by the quality of the genome assembly, and the prediction may be affected by the errors in the assembly.

The Limitations of the Concordance Metrics

The concordance metrics are a summary of the agreement between the two data types, but they do not capture the complexity of the relationship. The metrics are calculated for the entire dataset, and they do not identify the specific cases that are discordant. The metrics are also affected by the prevalence of the resistance, and the positive predictive value and the negative predictive value are affected by the prevalence of the resistance in the dataset.

The Professional Escalation Criteria

The analysis should be escalated to a senior colleague or a specialist when the discordant cases cannot be resolved. The escalation criteria include the following:

• The discordant case is a clinical isolate that is used for the treatment decision, and the discordance cannot be resolved.
• The discordant case is a case where the genotypic prediction is a resistance gene that is not in the database, and the resistance is not explained by the known mechanisms.
• The discordant case is a case where the phenotypic result is resistant, but the genotypic prediction is susceptible, and the resistance is not explained by the known mechanisms.
• The discordant case is a case where the MIC value is close to the breakpoint, and the repeat testing does not resolve the discordance.

The escalation should include the documentation of the discordant case, the review of the data, and the recommendation for the next steps. The escalation should be documented in the laboratory records.

The Role of the Laboratory in the Global Response

The laboratory is a critical component of the global response to antimicrobial resistance. The laboratory provides the data that are used for the surveillance, the stewardship, and the research. The laboratory must produce high-quality data that are comparable across the laboratories and across the time. The laboratory must use the standardized methods, the authenticated strains, and the validated databases. The laboratory must also participate in the external quality assessment programs to ensure the quality of the data.

The American Society for Microbiology (ASM) provides professional education and resources for the microbiology laboratory workforce. The ASM is a source of the professional standards and the best practices for the laboratory. The ASM also provides the training and the certification for the laboratory professionals. The laboratory professionals are the key to the quality of the data, and the professional development is essential for the quality of the data.

The Future of the Integrated Analysis

The integrated analysis is a rapidly evolving field. The cost of the whole genome sequencing is decreasing, and the sequencing is becoming more accessible to the clinical laboratories. The resistance gene databases are improving, and the prediction of the resistance is becoming more accurate. The integration of the phenotypic and the genotypic data is becoming a standard practice in the clinical laboratory.

The future of the integrated analysis will include the use of the machine learning and the artificial intelligence to improve the prediction of the resistance. The machine learning algorithms can be trained on the large datasets of the phenotypic and the genotypic data, and the algorithms can be used to predict the resistance from the genome sequence. The algorithms can also be used to identify the new resistance mechanisms and to improve the databases.

The future of the integrated analysis will also include the use of the real-time data. The sequencing can be performed in real time, and the data can be integrated with the phenotypic data in real time. The real-time integration will enable the rapid detection of the resistance and the rapid treatment decisions.

The Practical Steps for the Laboratory

The following are the practical steps for the laboratory that is implementing the integrated analysis:

1. Define the scope of the analysis, including the species, the drugs, and the source of the data.
2. Prepare the phenotypic data in a tabular format, with the isolate identifier, the drug name, and the MIC value.
3. Prepare the genotypic data in a tabular format, with the isolate identifier, the gene name, and the confidence score.
4. Harmonize the data by creating the mapping tables for the isolate identifiers and the drug names.
5. Merge the two data tables using the isolate identifier and the drug name.
6. Calculate the concordance metrics, including the categorical agreement, the sensitivity, the specificity, the positive predictive value, and the negative predictive value.
7. Identify the discordant cases and review each case individually.
8. Visualize the results using the scatter plots, the heatmaps, and the summary tables.
9. Document the analysis in a reproducible way, including the raw data, the scripts, and the versions of the software and the databases.
10. Escalate the unresolved discordant cases to the senior colleague or the clinical team.

The Records and the Measurements for the Laboratory

The laboratory should keep the records of the integrated analysis. The records should include the following:

• The raw data from the phenotypic AST and the genomic sequencing.
• The scripts and the code used for the analysis.
• The version of the resistance gene database.
• The version of the AST method.
• The date of the analysis.
• The name of the analyst.
• The discordant cases and the review of the discordant cases.

The records should be kept in a way that is reproducible and auditable. The records should be kept for the period that is required by the laboratory's quality management system.

The Quality Controls for the Integrated Analysis

The quality of the integrated analysis depends on the quality of the input data. The laboratory should use the following quality controls:

• The authenticated reference strains for the phenotypic AST, such as the strains from the ATCC.
• The quality control organisms for the AST, as described in the CLSI standards.
• The validated resistance gene database for the genotypic prediction.
• The quality control for the genome assembly, such as the coverage and the assembly metrics.
• The quality control for the resistance gene prediction, such as the identity and the coverage of the gene.

The quality controls should be documented in the laboratory records, and the results of the quality controls should be reviewed on a regular basis.

The Common Failure Patterns and the Solutions

The following are the common failure patterns and the solutions for the integrated analysis:

The Safety and the Regulatory Context

The laboratory should follow the biosafety guidelines for the handling of the bacterial cultures. The Biosafety in Microbiological and Biomedical Laboratories (BMBL) provides the guidelines for the risk assessment, the containment, and the decontamination of the laboratory. The BMBL is a joint publication of the CDC and the NIH, and it is the reference for the biosafety in the laboratory. The laboratory should follow the BMBL guidelines for the handling of the bacterial cultures, and the laboratory should be aware of the risk group of the organisms that are being handled.

The laboratory should also follow the regulatory requirements for the use of the antimicrobial agents. The use of the antimicrobial agents is regulated, and the laboratory should be aware of the regulations that apply to the use of the antimicrobial agents in the laboratory. The laboratory should also be aware of the regulations that apply to the use of the genomic data, and the laboratory should follow the regulations for the data privacy and the data security.

The Professional Development for the Laboratory

The laboratory professionals should participate in the professional development to maintain the skills and the knowledge. The American Society for Microbiology (ASM) provides the professional education and the resources for the laboratory professionals. The ASM provides the training, the certification, and the resources for the laboratory professionals. The laboratory professionals should use the ASM resources to maintain the skills and the knowledge.

The laboratory professionals should also participate in the proficiency testing programs. The proficiency testing programs are used to assess the quality of the laboratory, and the programs are used to identify the areas for the improvement. The laboratory professionals should participate in the proficiency testing programs to ensure the quality of the data.

The Limitations of the Analysis

The integrated analysis has the limitations that should be acknowledged. The analysis is limited by the quality of the input data, and the analysis is limited by the content of the resistance gene database. The analysis is also limited by the concordance metrics, which are a summary of the agreement and do not capture the full complexity of the relationship between the phenotype and the genotype.

The analysis should be used as a tool for the interpretation, and the analysis should not be used as a replacement for the clinical judgment. The analysis should be used in the context of the clinical and the laboratory data, and the analysis should be used to support the decisions, not to make the decisions.

Frequently Asked Questions

What is the difference between phenotypic and genotypic antimicrobial resistance data?

Phenotypic data measure the actual growth of the bacterium in the presence of the drug, expressed as a minimum inhibitory concentration or a categorical result. Genotypic data are the presence of resistance genes or mutations in the genome sequence. The phenotypic data are a direct measurement of the resistance, while the genotypic data are a prediction of the resistance based on the known genetic determinants.

Why do the phenotypic and genotypic results sometimes disagree?

The disagreement can occur because the presence of a resistance gene does not guarantee that the gene is expressed, and the resistance can be caused by mechanisms that are not in the gene database. The disagreement can also occur because the MIC value is close to the breakpoint, and the inherent variability of the test can cause the isolate to be classified differently.

What is the best way to harmonize the isolate identifiers and the drug names?

The best way is to create a mapping table that links the identifiers and the drug names. The mapping table should be verified by checking a sample of the isolates. The mapping table should be used to standardize the data before the merge.

What is the categorical agreement and how is it calculated?

The categorical agreement is the percentage of isolates for which the genotypic prediction and the phenotypic result are in agreement. It is calculated as the number of isolates with a resistant phenotype and a resistance determinant, plus the number of isolates with a susceptible phenotype and no resistance determinant, divided by the total number of isolates.

What should I do when I find a discordant case?

The discordant case should be reviewed individually. The review should include an examination of the MIC value, the specific resistance gene, the quality of the genome assembly, and the possibility of a technical error. The review should be documented, and the discordant case should be escalated if it cannot be resolved.

What is the role of the reference strains in the analysis?

The reference strains are used to validate the analytical methods and to ensure the quality of the data. The reference strains are authenticated and have known phenotypic and genotypic properties. The reference strains are used as the controls for the phenotypic AST and the genotypic prediction.

What are the limitations of the genotypic prediction?

The genotypic prediction is limited to the genes that are in the database. The prediction may miss the resistance genes that are not in the database, and the prediction may not be accurate if the gene is not expressed. The prediction is also limited by the quality of the genome assembly.

How should I document the integrated analysis?

The analysis should be documented in a reproducible way. The raw data, the scripts, the version of the database, and the version of the AST method should be recorded. The records should be kept in a way that is auditable and reproducible.

Related Bacteriology Guides

• Salmonellosis in Poultry: Serovar Surveillance, Antimicrobial Resistance, and Egg Safety
• Biological Foundation Models for Antimicrobial Peptide Discovery in Veterinary Pathogens
• Aeromonas hydrophila in Aquaculture: Virulence Factors and Antimicrobial Resistance
• Swine Bacterial Diseases: Colibacillosis, UTI, and Antimicrobial Resistance
• Avian Enrofloxacin: Pharmacology, Clinical Use, and Resistance in Poultry

References and Further Reading

• Biosafety in Microbiological and Biomedical Laboratories. CDC and NIH.
• Microbiology Resources. American Society for Microbiology.
• Antimicrobial Resistance. World Health Organization.
• Bacteriological Analytical Manual. U.S. Food and Drug Administration.
• Antimicrobial Susceptibility Testing. Clinical and Laboratory Standards Institute.
• Culture Collections. American Type Culture Collection.
• NCBI Pathogen Detection. National Center for Biotechnology Information.
• Conventional methods and future trends in antimicrobial susceptibility testing.. Saudi journal of biological sciences, 2023.
• The novel 2024 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations and superseded WHO N. gonorrhoeae reference strains-phenotypic, genetic and reference genome characterization.. The Journal of antimicrobial chemotherapy, 2024.
• Predicting Phenotypic Polymyxin Resistance in Klebsiella pneumoniae through Machine Learning Analysis of Genomic Data.. mSystems, 2020.
• Integrating serotyping, MLST, and phenotypic data: decoding the evolutionary drivers of Salmonella pathogenicity and drug resistance.. Applied and environmental microbiology, 2025.

This article is educational and does not replace validated laboratory procedures, clinical diagnosis, institutional biosafety review, or public-health guidance.